The Importance of Survival in Clinical Trials

Chadi hosts a duo of Canadiens to discuss quality of life and patient-reported outcomes in clinical trials: Christopher Booth, MD, and Michael Brundage, MSc, FRCPC, MD, both of Queen's University. They begin by pontificating on whether quality of life is a “must” endpoint in designing interventional clinical trials today, the timeline of how “PROs” came to be a term and an important component of clinical trials, how PRO measures should differ across disease types and trials, and how PROs should be approached from an organizational and operational standpoint. Then, they discuss and use examples to illustrate how practical it is for providers to regularly measure quality of life and PROs, how payers should be approached for discussion on PRO measures, whether toxicity of therapies are underestimated by providers, and a whole lot more.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/Watch all Healthcare Unfiltered episodes on Youtube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA